Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
BörsenkürzelCDXS
Name des UnternehmensCodexis Inc
IPO-datumApr 22, 2010
CEODr. Stephen G. Dilly, Ph.D.
Anzahl der mitarbeiter188
WertpapierartOrdinary Share
GeschäftsjahresendeApr 22
Addresse200 Penobscot Dr
StadtREDWOOD CITY
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94063
Telefon16504218100
Websitehttps://www.codexis.com/
BörsenkürzelCDXS
IPO-datumApr 22, 2010
CEODr. Stephen G. Dilly, Ph.D.
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten